A5064777057- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Asthma and respiratory diseases
- Renal and related cancers
- Allergic Rhinitis and Sensitization
- Genetic and Kidney Cyst Diseases
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Lymphoma Diagnosis and Treatment
- Respiratory and Cough-Related Research
- Genetic Syndromes and Imprinting
- Hedgehog Signaling Pathway Studies
- Inhalation and Respiratory Drug Delivery
- Inflammatory mediators and NSAID effects
- Genetic Associations and Epidemiology
- Erythropoietin and Anemia Treatment
- Ion Transport and Channel Regulation
- Lipid Membrane Structure and Behavior
- Monoclonal and Polyclonal Antibodies Research
- Pharmaceutical studies and practices
- Barrier Structure and Function Studies
- Biomedical Research and Pathophysiology
- Neuropeptides and Animal Physiology
- Erythrocyte Function and Pathophysiology
- Acute Myeloid Leukemia Research
GlaxoSmithKline (United States)
2023-2024
Bristol-Myers Squibb (United States)
2021-2022
Bristol-Myers Squibb (Switzerland)
2020
Regeneron (United States)
2013-2018
Merck & Co., Inc., Rahway, NJ, USA (United States)
2003-2009
Columbia University
1985-2001
Cornell University
1997
Duke University Hospital
1997
Duke Medical Center
1997
Washington University in St. Louis
1992
To compare efficacy and safety of sarilumab monotherapy with adalimumab in patients active rheumatoid arthritis (RA) who should not continue treatment methotrexate (MTX) due to intolerance or inadequate response.MONARCH was a randomised, active-controlled, double-blind, double-dummy, phase III superiority trial. Patients received (200 mg every 2 weeks (q2w)) (40 q2w) for 24 weeks. The primary end point change from baseline 28-joint disease activity score using erythrocyte sedimentation rate...
Objective To evaluate the efficacy and safety of sarilumab in combination with methotrexate (MTX) for treatment rheumatoid arthritis (RA). Methods Adults moderate‐to‐severe RA an inadequate response to MTX were randomized (1:1:1) receive (doses 150 mg or 200 mg) placebo every 2 weeks conjunction weekly 52 weeks. Co–primary end points proportion patients achieving American College Rheumatology 20% (ACR20) improvement responses at week 24, change from baseline Health Assessment Questionnaire...
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with active moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapy.Patients were randomly allocated receive 150 mg, 200 placebo every 2 weeks for 24 background DMARDs. The co-primary end points proportion achieving a according American College Rheumatology 20% criteria...
Autosomal dominant polycystic kidney disease (ADPKD) is a common human genetic characterized by cyst formation in tubules and other ductular epithelia. Cells lining the cysts have abnormalities cell proliferation polarity. The majority of ADPKD cases are caused mutations PKD1 gene, which codes for polycystin-1, large integral membrane protein unknown function that expressed on plasma renal tubular epithelial cells fetal kidneys. Because signaling from cell-cell cell-matrix adhesion complexes...
<h3>Objectives</h3> To evaluate safety and efficacy of weekly (qw) every other week (q2w) dosing sarilumab, a fully human anti-interleukin 6 receptor α (anti-IL-6Rα) monoclonal antibody, for moderate-to-severe rheumatoid arthritis (RA). <h3>Methods</h3> In this dose-ranging study, patients (n=306) with active RA, despite methotrexate, were randomly assigned to placebo or one five subcutaneous doses/regimens sarilumab: 100 mg q2w, 150 qw, 200 qw 12 weeks, plus methotrexate. The primary end...
Abstract Polygenic risk scores (PRS) for breast cancer have potential to improve prediction, but there is limited information on their utility in various clinical situations. Here we show that among 122,978 women the FinnGen study with 8401 cases, PRS modifies of two high-impact frameshift variants. Similarly, after diagnosis, individuals elevated an developing contralateral cancer, and can considerably assessment female first-degree relatives. In more detail, c.1592delT variant PALB2...
Exposure to CO2 acidifies the cytosol of mitochondria-rich cells in turtle bladder epithelium. The result decrease pH these, acid-secreting epithelium, is a transient increase cell calcium, which causes exocytosis vesicles containing proton-translocating ATPase. Because have rapid luminal membrane turnover, we were able identify single by their endocytosis rhodamine-tagged albumin. Using fluorescence emission 5,6-carboxyfluorescein at two excitation wavelengths, measured these identified and...
Abstract Large-scale biobank initiatives and commercial repositories store genomic data collected from millions of individuals, tools to leverage the rapidly growing pool health in disease prevention are needed. Here, we describe derivation validation genomics-enhanced risk for two common cardiometabolic diseases, coronary heart type 2 diabetes. Data used our analyses include FinnGen study (N = 309,154) UK Biobank project 343,672). The integrate contemporary genome-wide polygenic scores with...
Background: Proinflammatory mediators such as the cysteinyl leukotrienes are important in pathophysiology of allergic rhinitis. This study evaluated efficacy and tolerability montelukast, a leukotriene receptor antagonist, given once daily morning for treatment seasonal (fall) rhinitis 4 weeks. Methods: was randomized, double‐blind trial with placebo run‐in 4‐week period. Patients ( n = 1079) history positive skin test to pollen allergens were assigned placebo, montelukast 10 mg, or...
Interleukin 6 (IL-6) signaling plays a key role in the pathophysiology of rheumatoid arthritis (RA) and is inhibited by sarilumab, human monoclonal antibody blocking IL-6 receptor alpha (IL-6Rα). The effects sarilumab plus methotrexate (MTX) on serum biomarkers joint damage bone resorption were assessed two independent studies (phase II (part A) phase III B)) patients with RA history inadequate response to MTX from MOBILITY study (NCT01061736). Serum samples analyzed at baseline prespecified...
Key Points Patients with CKD face meaningful risk of heart failure hospitalization. Daprodustat compared darbepoetin was associated a nonsignificantly greater number hospitalizations in non-dialysis patients. Background are at higher failure. The hypoxia-inducible factor prolyl hydroxylase inhibitor daprodustat is an orally acting alternative to conventional injectable erythropoietin-stimulating agents (ESAs) for the treatment anemia patients CKD. Whether affects hospitalization unknown....
Objective: The purpose of this study was to determine the safety and tolerability profile montelukast 4-mg oral granules compared with placebo in children aged 6–24 months asthma.Methods: This a randomized, double-blind, placebo-controlled, parallel-group study. Children age at first visit history least three episodes physician-diagnosed asthma or 'asthma-like' symptoms need controller therapy were randomized either once daily evening for 6 weeks. primary variables frequency clinical...
The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab reducing disease activity and signs symptoms of RA, as well improving physical function, similar rates adverse serious events. We report the effects versus on patient-reported outcomes (PROs). Patients active RA intolerant of, or inadequate responders to, methotrexate...
Mutations in PKD1 cause autosomal dominant polycystic kidney disease (ADPKD), a common genetic which cysts form from tubules. The predicted product of this gene is novel protein with cell-adhesive and membrane-spanning domains. To test the hypothesis that polycystin, gene, cell adhesion molecule, we raised antibodies against peptides derived unduplicated, portion amino acid sequence. These recognized membrane-associated polypeptides 485 245 kDa human fetal homogenates. Expression was greater...
To examine 2-year safety, efficacy and radiographic outcomes of sarilumab in adults with RA inadequate response to MTX (MTX-IR).In the randomized, placebo-controlled MOBILITY trial, MTX-IR patients received subcutaneous (150 or 200 mg) placebo every 2 weeks (q2w) plus for up 1 year. Upon study completion, could enrol open-label, long-term extension (EXTEND, NCT011046652), which all mg q2w MTX. Dose reduction 150 was allowed abnormal laboratory findings per investigator's discretion.Of 1197...